Literature DB >> 2141780

Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci.

F W Goldstein1, A Coutrot, A Sieffer, J F Acar.   

Abstract

The activities of teicoplanin and vancomycin against 362 coagulase-negative staphylococci were determined by an agar dilution method. At the 4- and 32-micrograms/ml breakpoint levels of the National Committee for Clinical Laboratory Standards, 23.2% of the strains were intermediate and 1.7% were resistant to teicoplanin, in contrast to less than 0.3% intermediate to vancomycin. Resistant strains belonged to the species Staphylococcus epidermidis (74%) and S. haemolyticus (19%).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2141780      PMCID: PMC171714          DOI: 10.1128/AAC.34.5.899

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Microbiological properties of teicoplanin.

Authors:  D Greenwood
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

2.  In-vitro teicoplanin-resistance in coagulase-negative staphylococci from patients with endocarditis and from a cardiac surgery unit.

Authors:  E P Moore; D C Speller
Journal:  J Antimicrob Chemother       Date:  1988-04       Impact factor: 5.790

3.  Teicoplanin-resistant coagulase-negative staphylococcus.

Authors:  A P Wilson; M D O'Hare; D Felmingham; R N Grüneberg
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

4.  Teicoplanin-resistant coagulase-negative staphylococci.

Authors:  V Arioli; R Pallanza
Journal:  Lancet       Date:  1987-01-03       Impact factor: 79.321

5.  Teicoplanin-resistant coagulase-negative staphylococcus.

Authors:  A C Grant; R W Lacey; A M Brownjohn; J H Turney
Journal:  Lancet       Date:  1986-11-15       Impact factor: 79.321

6.  The effect of medium and inoculum on the activity of vancomycin and teicoplanin against coagulase-negative staphylococci.

Authors:  D Felmingham; K Solomonides; M D O'Hare; A P Wilson; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1987-10       Impact factor: 5.790

7.  Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci.

Authors:  E A Gorzynski; D Amsterdam; T R Beam; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

8.  Quality control limits for teicoplanin susceptibility tests and confirmation of disk diffusion interpretive criteria.

Authors:  A L Barry; R N Jones; T L Gavan; C Thornsberry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

  8 in total
  28 in total

1.  Relationship between glycopeptide use and decreased susceptibility to teicoplanin in isolates of coagulase-negative staphylococci.

Authors:  M Bertin; A Muller; X Bertrand; C Cornette; M Thouverez; D Talon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

2.  In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.

Authors:  F Biavasco; R Lupidi; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections.

Authors:  M Berti; G Candiani; M Borgonovi; P Landini; F Ripamonti; R Scotti; L Cavenaghi; M Denaro; B P Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 4.  Resistance of enterococci to glycopeptides.

Authors:  P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

5.  Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria.

Authors:  S Dutka-Malen; R Leclercq; V Coutant; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

Review 6.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  Penetration of teicoplanin into heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery.

Authors:  U K Frank; E Schmidt-Eisenlohr; D Mlangeni; M Schindler; A Hoh; F Beyersdorf; F D Daschner
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

8.  Jacques F. Acar (1931-2020).

Authors:  E Cambau; L Gutmann; J-L Mainardi; F Goldstein; A Buu-Hoi; E Collatz; M Poljak; G Kahlmeter; I Phillips; F Baquero
Journal:  Clin Microbiol Infect       Date:  2020-06-11       Impact factor: 8.067

9.  Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades.

Authors:  E Ahlstrand; K Svensson; L Persson; U Tidefelt; B Söderquist
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-05       Impact factor: 3.267

Review 10.  Teicoplanin: 10 years of clinical experience.

Authors:  M Trautmann; H Wiedeck; M Ruhnke; M Oethinger; R Marre
Journal:  Infection       Date:  1994 Nov-Dec       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.